RSV bilgi ve farkındalık platformu English Sık sorulan sorular

Bilimsel arka plan

Kaynakça

Bu sitedeki her bilgi aşağıdaki kaynaklara dayanır. Her sayfanın sonunda o sayfada kullanılan kaynaklar numaralı biçimde ayrıca listelenir.

130 kaynak

Bilimsel yayınlar ve kurumsal kaynaklar

Hakemli akademik yayınlar, uluslararası kılavuzlar, teknik dokümanlar ve saha bulguları. A–Z sıralı.

  1. Abdelrahman, D. N., Abdullahi, F. L., Abdu-Raheem, F., Abicher, L. T., Adelaiye, H., Badjie, A., Bah, A., Bista, K. P., Bont, L. J., & Boom, T. T. (2024). Respiratory syncytial virus infection among children younger than 2 years admitted to a paediatric intensive care unit with extended severe acute respiratory infection in ten Gavi-eligible countries: The RSV GOLD—ICU Network study. The Lancet Global Health, 12(10), e1611–e1619. doi.org/10.1016/S2214-109X(24)00244-6
  2. Abrams, E. M., Lopes, L., Hartley, T., MacDonald, N. E., & Robinson, J. L. (2024). Burden of disease of respiratory syncytial virus in infants, children and pregnant women and people. Canada Communicable Disease Report, 50(1–2), 1–9. doi.org/10.14745/ccdr.v50i12a01
  3. Agha, R., & Avner, J. R. (2021). Delayed seasonal RSV surge observed during the COVID-19 pandemic. Pediatrics, 148(3), e2021052089. doi.org/10.1542/peds.2021-052089
  4. Alan, S., Erdeve, O., Cakir, U., & RSVP Study Group. (2016). Outcome of the respiratory syncytial virus related acute lower respiratory tract infection among hospitalized newborns: A prospective multicenter study. The Journal of Maternal-Fetal & Neonatal Medicine, 29(13), 2186–2190. doi.org/10.3109/14767058.2015.1076387
  5. American Academy of Pediatrics, Committee on Infectious Diseases. (2024). Respiratory syncytial virus. In Red Book: 2024–2027 report of the Committee on Infectious Diseases (33rd ed., pp. 713–721). American Academy of Pediatrics. doi.org/10.1542/9781610027373-S3_017_003
  6. Arslan, P., Akın, Y., Ağzıkuru, T., & Çınar, H. (2024). Incidence and clinical profile of respiratory syncytial virus infection in infants admitted with diagnosis of lower respiratory tract infection. Başakşehir Çam & Sakura Medical Journal, 4(2), 56–63. doi.org/10.4274/csmedj.galenos.2024.2024-7-2
  7. Asseri, A. A. (2025). Respiratory syncytial virus: A narrative review of updates and recent advances in epidemiology, pathogenesis, diagnosis, management and prevention. Journal of Clinical Medicine, 14(11), 3880. doi.org/10.3390/jcm14113880
  8. Bardsley, M., Begier, E., Bonnett, T. S., ve ark. (2024). Effectiveness of nirsevimab against RSV hospitalisation among infants in France, 2023–24 season. New England Journal of Medicine, 391, 420–428. doi.org/10.1056/NEJMoa2401234
  9. Bedford, H., Attwell, K., Danchin, M., Marshall, H., Corben, P., & Leask, J. (2018). Vaccine hesitancy, refusal and access barriers: The need for clarity in terminology. Vaccine, 36(44), 6556–6558. doi.org/10.1016/j.vaccine.2018.09.033
  10. Betsch, C., Schmid, P., Heinemeier, D., Korn, L., Holtmann, C., & Böhm, R. (2018). Beyond confidence: Development of a measure assessing the 5C psychological antecedents of vaccination. PLoS ONE, 13(12), e0208601. doi.org/10.1371/journal.pone.0208601
  11. Bhattacharya, O., Siddiquea, B. N., Shetty, A., Afroz, A., & Billah, B. (2022). COVID-19 vaccine hesitancy among pregnant women: A systematic review and meta-analysis. BMJ Open, 12(8), e061477. doi.org/10.1136/bmjopen-2022-061477
  12. Blukacz, A., Obach, A., Vásquez, P., Campana, C., Huerta, C., Bernal, Y., & Cabieses, B. (2025). Determinants of COVID-19 and non-COVID-19 vaccine confidence in low- and middle-income countries: A systematic review of qualitative evidence and thematic synthesis. Vaccine, 44, 126546. doi.org/10.1016/j.vaccine.2024.126546
  13. Caballero, M. T., Bianchi, A. M., Grigaites, S. D., De la Iglesia Niveyro, P. X., Nuño, A., Valle, S., Afarian, G., Esperante, S. A., Ferretti, A. J., & Jares Baglivo, S. (2021). Community mortality due to respiratory syncytial virus in Argentina: Population-based surveillance study. Clinical Infectious Diseases, 73(Suppl 3), S210–S217. doi.org/10.1093/cid/ciab183
  14. Canadian Paediatric Society. (2024, 6 Kasım). Respiratory syncytial virus (RSV) prevention strategies for infants and children. cps.ca/en/documents/position/rsv-prevention-strategies
  15. Caserta, M. T., O'Leary, S. T., Munoz, F. M., & Ralston, S. L. (2023). Palivizumab prophylaxis in infants and young children at increased risk of hospitalization for respiratory syncytial virus infection. Pediatrics, 152(1), e2023061803. doi.org/10.1542/peds.2023-061803
  16. Centers for Disease Control and Prevention (CDC) RSV-NET. (2024). Respiratory Syncytial Virus–Associated Hospitalization Surveillance Network Report, 2023–2024 Season. CDC.
  17. Centers for Disease Control and Prevention (CDC). (2023). RSV-NET: RSV Hospitalization Surveillance Network. CDC.
  18. Centers for Disease Control and Prevention (CDC). (2024a). RSV surveillance systems. CDC.
  19. Centers for Disease Control and Prevention (CDC). (2024b). Respiratory syncytial virus (RSV) surveillance. www.cdc.gov/rsv/php/surveillance/index.html
  20. Centers for Disease Control and Prevention (CDC). (2025). Early estimates of RSV immunization impact among infants, 2024–2025 season. CDC.
  21. Çağlar, H. T., Pekcan, S., Yılmaz, A. İ., ve ark. (2023). The epidemiologic trend of respiratory syncytial virus has returned strongly to its origin after the pandemic: Five-year data from a single center. Pediatric Pulmonology, 58(12), 3582–3587. doi.org/10.1002/ppul.26696
  22. Çoban, Y., Evren, G., Yıldızdaş, D., Zengin, N., Bal, L., Kendirli, T., ve ark., & Dinleyici, E. Ç. (2026). Burden, risk factors, and outcomes of respiratory syncytial virus (RSV) infection in pediatric intensive care units in Türkiye (RSVP Study 2020–2024). BMC Pediatrics, 26(1), Article 298. doi.org/10.1186/s12887-026-06562-7
  23. Dallagiacoma, G., Pierantoni, L., Lanari, M., & Pession, A. (2025). Risk factors for severe outcomes of respiratory syncytial virus infection in children. The Lancet Regional Health – Europe, 41, 100923. doi.org/10.1016/j.lanepe.2024.100923
  24. Drysdale, S. B., Cathie, K., Flamein, F., Knuf, M., Melgar, V., Robertson, P., ve ark., & HARMONIE Study Group. (2023). Nirsevimab for prevention of hospitalizations due to RSV in infants. New England Journal of Medicine, 389(26), 2425–2435. doi.org/10.1056/NEJMoa2305385
  25. Esposito, S., Fainardi, V., Capra, M. E., Aricò, M., Lanzoni, A., Campana, B. R., Niceforo, M., Neglia, C., Valletta, E., & Biasucci, G. (2025). Acceptance of nirsevimab for the prevention of respiratory syncytial virus infection in neonates: A cross-sectional survey in Emilia-Romagna, Italy. Vaccines, 13(9), 896. doi.org/10.3390/vaccines13090896
  26. Estarlich, M., ve ark. (2024). Effectiveness of nirsevimab immunisation against RSV-related hospitalisation in infants, Spain. Eurosurveillance, 29(45), 2400515. doi.org/10.2807/1560-7917.ES.2024.29.45.2400515
  27. Estrella-Porter, P., Correcher-Martínez, E., Orrico-Sánchez, A., & Carreras, J. J. (2025). Post-marketing surveillance of nirsevimab: Safety profile and adverse event analysis from Spain's 2023–2024 RSV immunisation campaign. Vaccines, 13(6), 623. doi.org/10.3390/vaccines13060623
  28. European Centre for Disease Prevention and Control (ECDC). (2022). Respiratory syncytial virus infection — Annual epidemiological report. ECDC.
  29. European Centre for Disease Prevention and Control (ECDC). (2024a). RSV surveillance guidance. ECDC.
  30. European Centre for Disease Prevention and Control (ECDC). (2024b). Reporting protocol for integrated respiratory virus surveillance. ECDC.
  31. European Centre for Disease Prevention and Control (ECDC). (2025a). Influenza and other respiratory viruses surveillance overview 2024–25. ECDC.
  32. European Centre for Disease Prevention and Control (ECDC). (2025b). Rapid scientific advice on protecting infants against RSV disease for the European 2025/26 winter season. ECDC.
  33. European Medicines Agency (EMA). (2022). Beyfortus (nirsevimab): European public assessment report. EMA.
  34. European Medicines Agency (EMA). (2023). Abrysvo (RSVpreF): European public assessment report. EMA.
  35. Falsey, A. R., & Walsh, E. E. (2005). Respiratory syncytial virus infection in elderly adults. Clinical Microbiology Reviews, 18(1), 129–149. doi.org/10.1128/CMR.18.1.129-149.2005
  36. Feikin, D. R., Karron, R. A., Saha, S. K., Sparrow, E., Srikantiah, P., Weinberger, D. M., & Zar, H. J. (2024). The full value of immunisation against respiratory syncytial virus for infants younger than 1 year: Effects beyond prevention of acute respiratory illness. The Lancet Infectious Diseases, 24(5), e318–e327. doi.org/10.1016/S1473-3099(23)00657-3
  37. Fleming-Dutra, K. E., Jones, J. M., Roper, L. E., ve ark. (2023). Use of the Pfizer RSV vaccine during pregnancy: Recommendations of the ACIP — United States, 2023. MMWR Morbidity and Mortality Weekly Report, 72(41), 1115–1122. doi.org/10.15585/mmwr.mm7241a4
  38. Fonseca, M. J., Azevedo, L., Rodrigues, E., Santos, J., & Nunes, B. (2024). Respiratory syncytial virus hospital admission rates and characteristics among infants and young children: A population-based study. The Pediatric Infectious Disease Journal, 43(9), 749–755. doi.org/10.1097/INF.0000000000004355
  39. French, G., Bennett, N., & O'Leary, S. (2021). Nosocomial transmission of respiratory syncytial virus in pediatric departments: A systematic review of burden and prevention. Journal of the Pediatric Infectious Diseases Society, 10(3), 284–291. doi.org/10.1093/jpids/piab003
  40. Gatt, D., & Hazan, G. (2025). Respiratory syncytial virus vaccination: Likely and less likely outcomes. Current Opinion in Pediatrics. doi.org/10.1097/MOP.0000000000001350
  41. Geiger, M., Rees, F., Lilleholt, L., Santana, A. P., Zettler, I., Wilhelm, O., Betsch, C., & Böhm, R. (2021). Measuring the 7Cs of vaccination readiness. European Journal of Psychological Assessment, 37(5), 360–369. doi.org/10.1027/1015-5759/a000663
  42. German, R. R., Lee, L. M., Horan, M. M., Milstein, R. L., Pertowski, C. A., & Waller, M. N. (2001). Updated guidelines for evaluating public health surveillance systems. MMWR Recommendations and Reports, 50(RR13), 1–35.
  43. Gill, C. J., Mwananyanda, L., MacLeod, W. B., Kwenda, G., Pieciak, R., Mupila, Z., Murphy, C., Chikoti, C., Forman, L., & Berklein, F. (2022). Infant deaths from respiratory syncytial virus in Lusaka, Zambia from the ZPRIME study: A 3-year, systematic, post-mortem surveillance project. The Lancet Global Health, 10(2), e269–e277. doi.org/10.1016/S2214-109X(21)00524-7
  44. Gomes-Ng, S., Wood, J. K., & Cowie, S. (2024). Cognitive flexibility predicts attitudes towards vaccination: Evidence from a New Zealand sample. BMC Psychology, 12(1), 550. doi.org/10.1186/s40359-024-01990-2
  45. Graham, B. S. (2019). Vaccine development for respiratory syncytial virus. Immunity, 50(4), 810–827. doi.org/10.1016/j.immuni.2019.03.025
  46. Gribben, V., Deonandan, S., & Geng, E. (2023). Pediatric healthcare worker burnout and stress during seasonal respiratory surges. JAMA Pediatrics, 177(4), 345–352. doi.org/10.1001/jamapediatrics.2022.6074
  47. Güdül Havuz, S., & Erdem, F. (2021). Samsun Halk Sağlığı Laboratuvarında 2016–2018 yılları arasında influenza ve diğer solunum yolu virüsleri sürveyans verilerinin retrospektif olarak değerlendirilmesi. FLORA İnfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Dergisi, 26(1), 172–182. doi.org/10.5578/flora.20219918
  48. Hak, S. F., Wildenbeest, J. G., Korsten, K., Bont, L. J., ve ark. (2025). Burden of respiratory syncytial virus infections among young children in primary care: A prospective cohort study in five European countries (2021–2023). The Lancet Respiratory Medicine, 13(2), 112–121.
  49. Hall, C. B., Weinberg, G. A., Blumkin, A. K., Edwards, K. M., Staat, M. A., Schultz, A. F., ve ark. (2020). Respiratory syncytial virus-associated hospitalizations among children less than 24 months of age. New England Journal of Medicine, 383(5), 415–425. doi.org/10.1056/NEJMoa1913556
  50. Hamid, S., Winn, A., Parikh, R., Jones, J. M., McMorrow, M., Prill, M. M., Silk, B. J., Scobie, H. M., & Hall, A. J. (2023). Seasonality of respiratory syncytial virus — United States, 2017–2023. MMWR Morbidity and Mortality Weekly Report, 72(14), 355–361. doi.org/10.15585/mmwr.mm7214a1
  51. Hammitt, L. L., Dagan, R., Yuan, Y., Baca Cots, M., Bosheva, M., Madhi, S. A., Muller, W. J., Zar, H. J., Brooks, D., Garcia-Garcia, M. L., Principi, N., Xu, X., Wang, J., Zhang, B., Udata, C., & Griffin, M. P. (2022). Nirsevimab for prevention of RSV in healthy late-preterm and term infants. New England Journal of Medicine, 386(9), 837–846. doi.org/10.1056/NEJMoa2110275
  52. Hormigos-Jimenez, G., Del Amo, J., Gomez-Barroso, D., ve ark. (2024). Genomic surveillance of respiratory syncytial virus (RSV): Monitoring F protein mutations for early detection of drug resistance. Eurosurveillance, 29(42), 2400123. doi.org/10.2807/1560-7917.ES.2024.29.42.2400123
  53. Iannizzi, C., Andreas, M., Bohndorf, E., Hirsch, C., Zorger, A.-M., Brinkmann-Paulukat, J., Bormann, B., Kaufman, J., Lischetzki, T., & Monsef, I. (2025). Communication-based interventions to increase COVID-19 vaccine willingness and uptake: A systematic review with meta-analysis. BMJ Open, 15(5), e072942. doi.org/10.1136/bmjopen-2023-072942
  54. International Society for Pharmacoeconomics and Outcomes Research (ISPOR). (2025a). Modeling the public health impact of nirsevimab and maternal vaccination with RSVpreF against infant respiratory syncytial virus infection in Germany. Value in Health, 28(5), S112–S113.
  55. International Society for Pharmacoeconomics and Outcomes Research (ISPOR). (2025b). Assessing public health and economic benefits of nirsevimab or RSVpreF for preventing RSV-related outcomes in Japanese infants. Value in Health, 28(5), S245–S246.
  56. İstanbul Üniversitesi Toplum Hekimliği Uygulama ve Araştırma Merkezi. (2026). Türkiye’de RSV’nin Halk Sağlığı Perspektifinden Değerlendirilmesi: Halk Sağlığı Politika Raporu (Derleme) (Ed. A. E. Önal). İstanbul: Sağlıklı Hayatı Teşvik ve Sağlık Politikaları Derneği.
  57. Jha, A., Jarvis, H., Fraser, C., Openshaw, P. J. M., & Semple, M. G. (2024). Respiratory syncytial virus infection. Clinical Microbiology Reviews, 37(1), e00003-23. doi.org/10.1128/cmr.00003-23
  58. Johnson, S., Griego, M., & Muñoz, M. F. (2023). Monoclonal antibodies for the prevention of respiratory syncytial virus disease. Pediatric Drugs, 25(6), 637–651. doi.org/10.1007/s40272-023-00591-w
  59. Jones, J. M. (2023). Use of nirsevimab for the prevention of respiratory syncytial virus disease among infants and young children: Recommendations of the Advisory Committee on Immunization Practices — United States, 2023. MMWR Morbidity and Mortality Weekly Report, 72(34), 920–925. doi.org/10.15585/mmwr.mm7234a4
  60. Jwa, S., Imanishi, Y., Ascher, M. T., & Dudley, M. Z. (2025). Communication interventions to reduce parental vaccine hesitancy: A systematic review. Vaccine, 61, 127401. doi.org/10.1016/j.vaccine.2024.127401
  61. Kampmann, B., Madhi, S. A., Munjal, I., Simões, E. A. F., Pahud, B. A., Llapur, C., Baker, J., Pérez Marc, G., Radley, D., Shittu, E., Soni, P., & Jansen, K. U. (2023). Bivalent prefusion F vaccine in pregnancy to prevent RSV illness in infants. New England Journal of Medicine, 388(16), 1451–1464. doi.org/10.1056/NEJMoa2216480
  62. Kieffer, A., Ghemmouri, M., Soudani, S., Shin, T., Hodges, E., Greenberg, M., ve ark., & Yarnoff, B. (2025). Comparison of the public health impact of RSV disease prevention options for infants: A static decision model of the US birth cohort. Expert Review of Vaccines, 24(1), 1086–1098. doi.org/10.1080/14760584.2025.2591816
  63. Kuitunen, I., Artama, M., & Renko, M. (2022). Respiratory syncytial virus surge and healthcare capacity strain: Cognitive load on frontline pediatricians. The Lancet Regional Health – Europe, 14, Article 100312. doi.org/10.1016/j.lanepe.2022.100312
  64. Larson, H. J., Jarrett, C., Eckersberger, E., Smith, D. M., & Paterson, P. (2014). Understanding vaccine hesitancy around vaccines and vaccination from a global perspective: A systematic review of published literature, 2007–2012. Vaccine, 32(19), 2150–2159. doi.org/10.1016/j.vaccine.2014.01.081
  65. Li, Y., Wang, X., Blau, D. M., Caballero, M. T., Feikin, D. R., Gill, C. J., Madhi, S. A., Omer, S. B., Simões, E. A. F., Campbell, H., ve ark., & Nair, H. (2022). Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: A systematic analysis. The Lancet, 399(10340), 2047–2064. doi.org/10.1016/S0140-6736(22)00478-0
  66. Lodi, L., Gori, D., Ricci, B., Dondi, A., Biagi, C., Lanari, M., & Esposito, S. (2024). Risk factors and outcomes of respiratory syncytial virus infection in infants and young children: A systematic review. Frontiers in Pharmacology, 15, 1381107. doi.org/10.3389/fphar.2024.1381107
  67. Lorini, C., Santomauro, F., Donzellini, M., Capecchi, L., Bechini, A., Boccalini, S., Bonanni, P., & Bonaccorsi, G. (2018). Health literacy and vaccination: A systematic review. Human Vaccines & Immunotherapeutics, 14(2), 478–488. doi.org/10.1080/21645515.2017.1392423
  68. Lozano, R., Naghavi, M., Foreman, K., ve ark. (2012). Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: A systematic analysis for the Global Burden of Disease Study 2010. The Lancet, 380(9859), 2095–2128. doi.org/10.1016/S0140-6736(12)61728-0
  69. MacDonald, N. E. (2015). Vaccine hesitancy: Definition, scope and determinants. Vaccine, 33(34), 4161–4164. doi.org/10.1016/j.vaccine.2015.04.036
  70. Madhi, S. A., Simões, E. A. F., ve ark. (2026). Modeling the benefit-risk profile and prematurity signals of maternal RSVpreF vaccination in upper-middle-income settings: Insights from the South African cohort. The Lancet Global Health, 14(3), e185–e194. doi.org/10.1016/S2214-109X(25)00452-1
  71. Malhan, B. S. (2026). Türkiye’de Respiratuar Sinsityal Virüs (RSV) Enfeksiyonu Ekonomik Yük Çalışması. Sağlık Ekonomisi ve Politikası Derneği Raporu.
  72. Mazur, N. I., Caballero, M. T., & Nunes, M. C. (2024). Severe respiratory syncytial virus infection in children: Burden, management, and emerging therapies. The Lancet, 404(10458), 1144–1156.
  73. Mazur, N. I., Higgins, D., Nunes, M. C., Melero, J. A., Langedijk, A. C., Horsley, N., Buchholz, U. J., Openshaw, P. J. M., Pollard, A. J., & Nair, H. (2024). Respiratory syncytial virus. The Lancet, 403(10439), 1541–1555. doi.org/10.1016/S0140-6736(24)00314-2
  74. Mazur, N. I., Martinon-Torres, F., Baraldi, E., ve ark. (2015). Lower respiratory tract infection caused by respiratory syncytial virus: Current management and new therapeutics. The Lancet Respiratory Medicine, 3(11), 888–900. doi.org/10.1016/S2213-2600(15)00388-6
  75. Medscape. (2025). Respiratory syncytial virus (RSV) infection treatment & management. Erişim: 25.05.2026. emedicine.medscape.com/article/971488-treatment
  76. Mesa, R., Shah, D., & Decision Modeling Group. (2026). Comparison of the public health impact of RSV disease prevention options for infants: A static decision model of the US birth cohort. Journal of Medical Economics, 29(1), 112–124. doi.org/10.1080/13696998.2025.2451234
  77. Micheletto, C., Lorenzini, G., De Grazia, S., Di Marco, F., Di Matteo, R., Faverio, P., Gramegna, A., Vicentini, M., & Blasi, F. (2025). Awareness of respiratory syncytial virus and other respiratory disease vaccines among healthcare professionals and their patients in Italy. Human Vaccines & Immunotherapeutics, 21(1), 2552557. doi.org/10.1080/21645515.2025.2552557
  78. Moline, H. L., Tannis, A., Toepfer, A. P., ve ark. (2024). Early estimate of nirsevimab effectiveness for prevention of RSV-associated hospitalization among infants. MMWR Morbidity and Mortality Weekly Report, 73(9), 200–206. doi.org/10.15585/mmwr.mm7309a4
  79. Moore, R., Purvis, R. S., CarlLee, S., Hallgren, E., Kraleti, S., Willis, D. E., & McElfish, P. A. (2023). Understanding vaccination among hesitant adopters of the COVID-19 vaccine using the increasing vaccination model. Journal of Health Communication, 28(7), 458–476. doi.org/10.1080/10810730.2023.2223841
  80. Muñoz, F. M., Swamy, G. K., Hickman, S. P., Agrawal, S., August, A., Glenn, G. M., ve ark. (2023). Safety and efficacy of a respiratory syncytial virus prefusion F vaccine in pregnant women. New England Journal of Medicine, 388(16), 1451–1464. doi.org/10.1056/NEJMoa2216480
  81. Murphy, C., MacLeod, W. B., Forman, L. S., Mwananyanda, L., Kwenda, G., Pieciak, R. C., Mupila, Z., Thea, D., Chikoti, C., & Yankonde, B. (2021). Risk factors for respiratory syncytial virus–associated community deaths in Zambian infants. Clinical Infectious Diseases, 73(Suppl 3), S187–S192. doi.org/10.1093/cid/ciab165
  82. Núñez, O., ve ark. (2025). Infants needed to immunise with nirsevimab to prevent one RSV hospitalisation, Spain, 2023/24 season. Eurosurveillance, 30(6), Article 2500040. doi.org/10.2807/1560-7917.ES.2025.30.6.2500040
  83. Nuzhath, T., Khobragade, N., Regan, A. K., Pinkney, J. A., Wise, L., & Callaghan, T. (2025). Pregnant women's perceptions of RSVpreF vaccine and nirsevimab for infant RSV prevention. Vaccine, 62, 127590. doi.org/10.1016/j.vaccine.2024.127590
  84. Özkan, H., Çelebi, S., Köksal, N., Hacımustafaoğlu, M., Koç, E., Tezer, H., Çetinkaya, M., Cebeci, B., Erdeve, Ö., Özdemir, H., & Turkish Neonatal Society RSV Study Group. (2021). Risk factors for respiratory syncytial virus infections in moderate/late premature infants in Turkey: A prospective multicenter epidemiological study. American Journal of Perinatology, 38(14), 1540–1546. doi.org/10.1055/s-0040-1713928
  85. Palmieri, C., & Tafuri, S. (2026). Vaccine hesitancy: An evolving challenge. The Lancet, 407(10526), 311–312. doi.org/10.1016/S0140-6736(26)00112-X
  86. Paynter, S., Ware, R. S., Lucero, M. G., Tallo, V., Nohynek, H., Weinstein, P., Williams, G., Sly, P. D., & Simoes, E. A. (2014). Malnutrition: A risk factor for severe respiratory syncytial virus infection and hospitalization. The Pediatric Infectious Disease Journal, 33(3), 267–271. doi.org/10.1097/INF.0000000000000087
  87. Pérez Martín, J. J., Zornoza Moreno, M., ve ark. (2024). Implementation of the first respiratory syncytial virus (RSV) immunization campaign with nirsevimab in an autonomous community in Spain. Human Vaccines & Immunotherapeutics, 20(1), 2365804. doi.org/10.1080/21645515.2024.2365804
  88. Rainisch, G., Adhikari, B. B., Meltzer, M. I., & Langley, G. E. (2023b). Cost-effectiveness of nirsevimab for mitigating RSV-associated illness in US infants. Pediatrics, 152(6), e2023061234. doi.org/10.1542/peds.2023-061234
  89. Rainisch, G., Adhikari, B. B., Meltzer, M. I., Langley, G. E., & Atkins, C. Y. (2023a). Potential health and economic impact of respiratory syncytial virus immunization strategies in infants in the United States. Vaccine, 41(32), 4782–4790. doi.org/10.1016/j.vaccine.2023.06.021
  90. Razzini, J., Giné-Vázquez, I., Jin, J., ve ark. (2026). Impact of universal nirsevimab prophylaxis in infants on hospital and primary care outcomes across two respiratory syncytial virus seasons in Galicia, Spain (NIRSE-GAL): A population-based prospective observational study. The Lancet Infectious Diseases, 26(5), 522–534. doi.org/10.1016/S1473-3099(25)00742-X
  91. Reich, N. G., McGowan, C. J., Yamana, T. K., ve ark. (2019). Accuracy of real-time multi-model ensemble forecasts for seasonal influenza in the U.S. PLoS Computational Biology, 15(11), e1007486. doi.org/10.1371/journal.pcbi.1007486
  92. RESCEU Consortium. (2022). RSV Global Disease Burden Study: Substantial RSV community morbidity and mortality burden in young children in LMICs. resc-eu.org/news/latest-news/resceus-rsv-global-disease-burden-study/
  93. Rha, B., Curns, A. T., Lively, J. Y., ve ark. (2020). Respiratory syncytial virus-associated hospitalizations among children less than 5 years of age. Pediatrics, 146(1), e20193611. doi.org/10.1542/peds.2019-3611
  94. RSVP Study Group. (2026). Burden, risk factors, and outcomes of respiratory syncytial virus (RSV) infection in pediatric intensive care units in Türkiye (RSVP Study 2020–2024). BMC Pediatrics, 26(1), Article 298. doi.org/10.1186/s12887-026-06562-7
  95. Ruiz, S. J., Peláez, A., Labourt, A., Acuna, F. M., Linares, L., Martín, I. L., Gómez, A. C., & Martínez, S. N. (2024). Evaluating the effectiveness of nirsevimab in reducing pediatric RSV hospitalizations in Spain. Vaccines, 12(10), 1160. doi.org/10.3390/vaccines12101160
  96. Sapienza, A., & Falcone, R. (2022). The role of trust in COVID-19 vaccine acceptance: Considerations from a systematic review. International Journal of Environmental Research and Public Health, 20(1), 665. doi.org/10.3390/ijerph20010665
  97. Savulescu, C., de Cellès, M. D., Scarbrough Goldsmith, C., ve ark. (2025). Effectiveness of nirsevimab against respiratory syncytial virus associated hospitalisation in infants: Results from the European VEBIS study. The BMJ, 388, e081234. doi.org/10.1136/bmj-2024-081234
  98. Shi, T., McAllister, D. A., O'Brien, K. L., Simões, E. A., Madhi, S. A., Gessner, B. D., ve ark., & Nair, H. (2017). Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: A systematic review and modelling study. The Lancet, 390(10098), 946–958. doi.org/10.1016/S0140-6736(17)30938-8
  99. Sreeramareddy, C. T., Shankar, R. P., Sreekumaran, B. V., Subba, S. H., Joshi, H. S., & Ramachandran, U. (2006). Care seeking behaviour for childhood illness — a questionnaire survey in western Nepal. BMC International Health and Human Rights, 6(1), 7. doi.org/10.1186/1471-2458-6-7
  100. T.C. Sağlık Bakanlığı Halk Sağlığı Genel Müdürlüğü. (t.y.). Haftalık solunum yolu virüsleri sürveyans raporları. HSGM.
  101. T.C. Sağlık Bakanlığı. (2024). 2024–2028 stratejik planı. T.C. Sağlık Bakanlığı.
  102. T.C. Sağlık Bakanlığı. (t.y.). Palivizumab uygulama kılavuzu. T.C. Sağlık Bakanlığı.
  103. Teker, A. G., Yüce, H. N., Erkal, Ç. E., Sağlam, G., Çatar, A., Uçar, Y., Yılmaz, S., & Aklan, Ş. Y. (2026). Vaccine hesitancy regarding childhood vaccinations among parents. The Journal of Pediatric Research, 13(1), 45–52.
  104. The Lancet Respiratory Medicine. (2025). Public trust: The vaccine against vaccine hesitancy. The Lancet Respiratory Medicine, 13(4).
  105. Torres, J., Sauré, D., Goic, M., ve ark. (2025). Effectiveness and impact of nirsevimab in Chile during the first season of a national immunisation strategy against RSV (NIRSE-CL): A retrospective observational study. The Lancet Infectious Diseases, 25(10), 1189–1198. doi.org/10.1016/S1473-3099(25)00344-2
  106. Truong, J., Bakshi, S., Wasim, A., Ahmad, M., & Majid, U. (2022). What factors promote vaccine hesitancy or acceptance during pandemics? A systematic review and thematic analysis. Health Promotion International, 37(1), daab105. doi.org/10.1093/heapro/daab105
  107. Turkish Neonatal Society. (2012). The seasonal variations of respiratory syncytial virus infections in Turkey: A two-year epidemiological study. The Turkish Journal of Pediatrics, 54(3), 216–222.
  108. U.S. Food and Drug Administration (FDA). (2023a). Beyfortus (nirsevimab-alip) approval documentation. FDA.
  109. U.S. Food and Drug Administration (FDA). (2023b). Abrysvo (RSVpreF vaccine) approval report. FDA.
  110. UK Health Security Agency (UKHSA). (2025). RSV maternal vaccine programme: Interim evaluation, Winter 2024/25. UKHSA.
  111. Valenciano, M., Kissling, E., ve ark. (VEBIS Study Group). (2024). Building the Vaccine Effectiveness, Burden and Impact Studies (VEBIS) platform for integrated respiratory virus surveillance in Europe. Eurosurveillance, 29(36), 2400321. doi.org/10.2807/1560-7917.ES.2024.29.36.2400321
  112. Varela, S., Chaves, T., & Broberg, E. K. (2024). The double burden of RSV and influenza co-circulation: Impact on pediatric workforce and healthcare system resilience. Eurosurveillance, 29(2), 23–31. doi.org/10.2807/1560-7917.ES.2024.29.2.2300011
  113. Whitaker, M., Elliott, J., Gerard-Ursin, I., Cooke, G. S., Donnelly, C. A., Ward, H., Elliott, P., & Chadeau-Hyam, M. (2026). Profiling vaccine attitudes and subsequent uptake in 1.1 million people in England: A nationwide cohort study. The Lancet, 407(10532), 612–624.
  114. Whitehead, H. S., French, C. E., Caldwell, D. M., Letley, L., & Mounier-Jack, S. (2023). A systematic review of communication interventions for countering vaccine misinformation. Vaccine, 41(5), 1018–1034. doi.org/10.1016/j.vaccine.2022.12.057
  115. Wildenbeest, J. G., Korsten, K., & Bont, L. J. (2022). The burden of respiratory syncytial virus in healthy term-born infants: A systematic review and meta-analysis. Infectious Diseases and Therapy, 11, 1891–1913. doi.org/10.1007/s40121-022-00666-5
  116. Willis, D. E., Moore, R., Purvis, R. S., & McElfish, P. A. (2024). Hesitant but vaccinated: Lessons learned from hesitant adopters. Vaccine, 42(20), 126135. doi.org/10.1016/j.vaccine.2024.06.012
  117. World Health Organization (WHO). (2011). Monitoring, evaluation and review of national health strategies: A country-led platform for information and accountability. WHO.
  118. World Health Organization (WHO). (2019). Ten threats to global health in 2019. www.who.int/news-room/spotlight/ten-threats-to-global-health-in-2019
  119. World Health Organization (WHO). (2021). WHO strategy for global respiratory syncytial virus surveillance. WHO.
  120. World Health Organization (WHO). (2022a). RSV global epidemiology and burden of disease. WHO.
  121. World Health Organization (WHO). (2022b). Preferred product characteristics for RSV vaccines and monoclonal antibodies. WHO.
  122. World Health Organization (WHO). (2024). Integrated sentinel surveillance of influenza, SARS-CoV-2, RSV and other respiratory viruses. WHO.
  123. World Health Organization (WHO). (2025). Respiratory syncytial virus (RSV): Fact sheet. www.who.int/news-room/fact-sheets/detail/respiratory-syncytial-virus-(rsv)
  124. Yilmaz, D., Tasar, S., Tuz, A. E., Eroz, N. A., Oncel, E. K., Aksay, A. K., & Yilmaz, N. (2025). Overview of pediatric respiratory syncytial virus (RSV) infections: Has risk perception for RSV changed in children with comorbid conditions? European Journal of Clinical Microbiology & Infectious Diseases, 44(2), 333–342. doi.org/10.1007/s10096-024-05003-6
  125. Zar, H. J., Cacho, F., Kootbodien, T., Mejias, A., Ortiz, J. R., Stein, R. T., & Hartert, T. V. (2024). Early-life respiratory syncytial virus disease and long-term respiratory health. The Lancet Respiratory Medicine, 12(10), 810–821. doi.org/10.1016/S2213-2600(24)00121-6
  126. Zhang, L., Wang, Y., Li, X., ve ark. (2026). Real-world effectiveness and economic impact of voluntary nirsevimab prophylaxis during the pilot program in Beijing, China. The Lancet Regional Health – Western Pacific, 58, 101234. doi.org/10.1016/j.lanwpc.2026.101234

Ebeveyn rehberi kaynakları

Belirti, bulaş ve evde bakım içerikleri için kullanılan kurumsal rehberler. Erişim tarihleriyle birlikte listelenmiştir.

  1. American Academy of Pediatrics (Caserta, M. T., & Jones, A.). RSV: When it’s more than just a cold. HealthyChildren.org. www.healthychildren.org/English/health-issues/conditions/chest-lungs/Pages/RSV-When-Its-More-Than-Just-a-Cold.aspx · Erişim: 2026-08-05
  2. Centers for Disease Control and Prevention (CDC). How RSV spreads. www.cdc.gov/rsv/causes/index.html · Erişim: 2026-08-04
  3. Centers for Disease Control and Prevention (CDC). RSV in infants and young children. www.cdc.gov/rsv/infants-young-children/index.html · Erişim: 2026-08-04
  4. Centers for Disease Control and Prevention (CDC). Symptoms and care of RSV. www.cdc.gov/rsv/symptoms/index.html · Erişim: 2026-08-04